Invention Grant
- Patent Title: Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
-
Application No.: US17234841Application Date: 2021-04-20
-
Publication No.: US11697678B2Publication Date: 2023-07-11
- Inventor: Elvire Gouze , Stéphanie Garcia
- Applicant: Pfizer Inc. , INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Côte d'Azur
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.,INSERM (Institut National de la Santé et de la Recherche Médicale),Université Côte d'Azur
- Current Assignee: Pfizer Inc.,INSERM (Institut National de la Santé et de la Recherche Médicale),Université Côte d'Azur
- Current Assignee Address: US NY New York; FR Paris; FR Nice
- Agency: Wolf, Greenfield & Sacks, P.C.
- The original application number of the division: US16417174 2019.05.20
- Main IPC: A61K38/17
- IPC: A61K38/17 ; C07K14/71 ; A61P19/00 ; A61K38/00
Abstract:
The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth regardation disorders, such as achondroplasia.
Public/Granted literature
- US20210309718A1 SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES AND USES THEREOF Public/Granted day:2021-10-07
Information query
IPC分类:
